{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:04:44Z","timestamp":1784081084430,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00771-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:24:18Z","timestamp":1779427458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of clinical benefit and cost-effectiveness on reimbursement decisions for lung cancer drugs in Spain"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-7937","authenticated-orcid":false,"given":"Pelayo","family":"Nieto-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-2730","authenticated-orcid":false,"given":"Celia","family":"Casta\u00f1o-Amores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-6993","authenticated-orcid":false,"given":"Antonio Jos\u00e9","family":"Garc\u00eda-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-0307","authenticated-orcid":false,"given":"Juan","family":"Oliva-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"771_CR2","unstructured":"Instituto Nacional de Estad\u00edstica (INE). [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.ine.es\/."},{"issue":"5","key":"771_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10198-011-0344-9","volume":"13","author":"J Oliva-Moreno","year":"2012","unstructured":"Oliva-Moreno J. Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain\u2019s economy? Eur J Health Econ. 2012;13(5):605\u201314. https:\/\/doi.org\/10.1007\/s10198-011-0344-9.","journal-title":"Eur J Health Econ"},{"issue":"10","key":"771_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","volume":"28","author":"NI Cherny","year":"2017","unstructured":"Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340\u201366.","journal-title":"Ann Oncol"},{"issue":"23","key":"771_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015;33(23):2563\u201377.","journal-title":"J Clin Oncol"},{"key":"771_CR6","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Le service m\u00e9dical rendu (SMR) et l\u2019am\u00e9lioration du service m\u00e9dical rendu (ASMR) [Internet]. [cited 2024 Mar 13]. Available from: https:\/\/www.has-sante.fr\/jcms\/r_1506267\/fr\/le-service-medical-rendu-smr-et-l-amelioration-du-service-medical-rendu-asmr."},{"key":"771_CR7","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG) [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.iqwig.de\/en\/."},{"issue":"3","key":"771_CR8","doi-asserted-by":"publisher","first-page":"100166","DOI":"10.1016\/j.esmoop.2021.100166","volume":"6","author":"N Gr\u00f6ssmann","year":"2021","unstructured":"Gr\u00f6ssmann N, Wolf S, Rothschedl E, Wild C. Twelve years of European cancer drug approval\u2014a systematic investigation of the magnitude of clinical benefit. ESMO Open. 2021;6(3):100166.","journal-title":"ESMO Open"},{"issue":"9","key":"771_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/0284186X.2021.1942546","volume":"60","author":"R Garc\u00eda-Fumero","year":"2021","unstructured":"Garc\u00eda-Fumero R, Fern\u00e1ndez-L\u00f3pez C, Calleja-Hern\u00e1ndez M\u00c1, Exp\u00f3sito-Hern\u00e1ndez J. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1. Acta Oncol. 2021;60(9):1225\u201332.","journal-title":"Acta Oncol"},{"issue":"5","key":"771_CR10","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1200\/JOP.17.00058","volume":"14","author":"R Saluja","year":"2018","unstructured":"Saluja R, Arciero VS, Cheng S, McDonald E, Wong WWL, Cheung MC, et al. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. J Oncol Pract. 2018;14(5):e280\u201394.","journal-title":"J Oncol Pract"},{"issue":"3","key":"771_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","volume":"15","author":"S Vogler","year":"2017","unstructured":"Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, Pedersen HB, Dedet G, Babar ZU. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Appl Health Econ Health Policy. 2017;15(3):307\u201321. https:\/\/doi.org\/10.1007\/s40258-016-0300-z.","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"771_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40258-023-00867-9","volume":"22","author":"N Zozaya","year":"2024","unstructured":"Zozaya N, Villaseca J, Fern\u00e1ndez I, Abdalla F, Cadenas-Nore\u00f1a B, Calleja M\u00c1, G\u00f3mez-Pajuelo P, Mestre-Ferr\u00e1ndiz J, Oliva-Moreno J, Trillo JL, Hidalgo-Vega \u00c1. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Appl Health Econ Health Policy. 2024;22(3):297\u2013313. https:\/\/doi.org\/10.1007\/s40258-023-00867-9.","journal-title":"Appl Health Econ Health Policy"},{"key":"771_CR13","unstructured":"Real Decreto Legislativo 1\/. 2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garant\u00edas y uso racional de los medicamentos y productos sanitarios."},{"key":"771_CR14","unstructured":"Ministerio de Sanidad. Plan para la consolidaci\u00f3n de los informes de posicionamiento terap\u00e9utico de los medicamentos en el Sistema Nacional de Salud. 8 Jul 2020. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/IPT\/docs\/20200708.Plan_de_accion_para_la_consolidacion_de_los_IPT.actCPF8Julio.pdf."},{"key":"771_CR15","unstructured":"Vallejo-Torres L, Oliva-Moreno J, Lobo F. Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement. Health Econ Policy Law. 2024 Dec 12;1\u201313."},{"key":"771_CR16","unstructured":"Audiencia Nacional. Sala de lo Contencioso-Administrativo. Secci\u00f3n Octava. Sentencia n\u00fam. 0000123\/2021. 2023."},{"issue":"2","key":"771_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10198-023-01584-9","volume":"25","author":"P Nieto-G\u00f3mez","year":"2024","unstructured":"Nieto-G\u00f3mez P, Casta\u00f1o-Amores C, Rodr\u00edguez-Delgado A, \u00c1lvarez-S\u00e1nchez R. Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement. Eur J Health Econ. 2024;25(2):257\u201367.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"771_CR18","first-page":"240","volume":"37","author":"I Oyag\u00fcez","year":"2013","unstructured":"Oyag\u00fcez I, Fr\u00edas C, Segu\u00ed M\u00c1, G\u00f3mez-Barrera M, Casado M\u00c1, Gorgas MQ. Eficiencia de tratamientos oncol\u00f3gicos para tumores s\u00f3lidos en Espa\u00f1a. Farm Hosp. 2013;37(3):240\u201359.","journal-title":"Farm Hosp"},{"key":"771_CR19","doi-asserted-by":"crossref","unstructured":"Elvira D, Torres F, Vives R, Obach M, Pontes C. Reporting reimbursement price decisions for onco-hematology drugs in Spain. Front Public Health. 2023;11. Available from: https:\/\/www.frontiersin.org\/journals\/public-health\/articles\/10.3389\/fpubh.2023.1265323\/full.","DOI":"10.3389\/fpubh.2023.1265323"},{"key":"771_CR20","unstructured":"Centro de Informaci\u00f3n de Medicamentos de la AEMPS (CIMA). [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/cima.aemps.es\/cima\/publico\/home.html."},{"key":"771_CR21","unstructured":"Ministerio de Sanidad. - Profesionales de la Salud - Buscador situaci\u00f3n financiaci\u00f3n medicamentos [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do."},{"key":"771_CR22","unstructured":"ESMO. ESMO-MCBS Scorecards [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards."},{"key":"771_CR23","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Professionnels [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.has-sante.fr\/jcms\/fc_2873790\/fr\/professionnels."},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"e077391","DOI":"10.1136\/bmj-2023-077391","volume":"384","author":"F Brinkhuis","year":"2024","unstructured":"Brinkhuis F, Goettsch WG, Mantel-Teeuwisse AK, Bloem LT. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. BMJ. 2024;384:e077391.","journal-title":"BMJ"},{"key":"771_CR25","unstructured":"BOTPLUS [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/botplusweb.farmaceuticos.com\/."},{"key":"771_CR26","unstructured":"BOE-A-2010-8228. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2010-8228."},{"key":"771_CR27","unstructured":"Ortega Eslava A, Mar\u00edn Gil R, Fraga Fuentes MD, L\u00f3pez-Briz E, Puigvent\u00f3s Latorre F. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/gruposdetrabajo.sefh.es\/."},{"key":"771_CR28","unstructured":"Ministerio de Sanidad. Sanidad en datos - Estad\u00edsticas y Estudios - Atlas de la Sanidad en Espa\u00f1a [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/inforRecopilaciones\/atlas\/atlasDatos.htm."},{"key":"771_CR29","unstructured":"CDA-AMC [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.cadth.ca\/."},{"key":"771_CR30","unstructured":"NICE. NICE | The national institute for health and care excellence [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.nice.org.uk\/."},{"key":"771_CR31","unstructured":"Tufts CEA. [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/cear.tuftsmedicalcenter.org\/."},{"key":"771_CR32","unstructured":"Ministerio de Sanidad. - Profesionales de la Salud - Nomenclator [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/sede.mscbs.gob.es\/gl\/ciudadanos\/procAdministrativos.do?tipo=detallar&cod=993594."},{"key":"771_CR33","unstructured":"The OECD. Conversion rates - exchange rates - OECD Data [Internet]. [cited 2024 Apr 1]. Available from: http:\/\/data.oecd.org\/conversion\/exchange-rates.htm."},{"key":"771_CR34","unstructured":"Instituto Nacional de Estad\u00edstica. El IPC en un clic [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/www.ine.es\/calcula\/."},{"issue":"10","key":"771_CR35","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/hec.3086","volume":"24","author":"H Dakin","year":"2015","unstructured":"Dakin H, Devlin N, Feng Y, Rice N, O\u2019Neill P, Parkin D. The Influence of Cost-Effectiveness and Other Factors on NICE Decisions. Health Econ. 2015;24(10):1256\u201371.","journal-title":"Health Econ"},{"issue":"5","key":"771_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hec.864","volume":"13","author":"N Devlin","year":"2004","unstructured":"Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437\u201352.","journal-title":"Health Econ"},{"issue":"11","key":"771_CR37","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","volume":"33","author":"M Svensson","year":"2015","unstructured":"Svensson M, Nilsson FO, Arnberg K. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness. PharmacoEconomics. 2015;33(11):1229\u201336.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"771_CR38","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bcp.13531","volume":"84","author":"SM Wallerstedt","year":"2018","unstructured":"Wallerstedt SM, Henriksson M. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions. Br J Clin Pharmacol. 2018;84(6):1146\u201355.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"771_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","volume":"41","author":"P Russo","year":"2023","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service. PharmacoEconomics. 2023;41(1):107\u201317.","journal-title":"PharmacoEconomics"},{"issue":"10","key":"771_CR40","doi-asserted-by":"publisher","first-page":"e0206121","DOI":"10.1371\/journal.pone.0206121","volume":"13","author":"EY Bae","year":"2018","unstructured":"Bae EY, Kim HJ, Lee HJ, Jang J, Lee SM, Jung Y, et al. Role of economic evidence in coverage decision-making in South Korea. PLoS ONE. 2018;13(10):e0206121.","journal-title":"PLoS ONE"},{"issue":"9","key":"771_CR41","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/11591530-000000000-00000","volume":"30","author":"WG Linley","year":"2012","unstructured":"Linley WG, Hughes DA. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. PharmacoEconomics. 2012;30(9):779\u201394.","journal-title":"PharmacoEconomics"},{"key":"771_CR42","unstructured":"GENESIS-SEFH [Internet]. [cited 2024 Sep 10]. Available from: https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Enlaces\/InformesHosp_abc.htm?ml=1."},{"key":"771_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/CEOR.S136657","volume":"9","author":"M Pignata","year":"2017","unstructured":"Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, et al. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:655\u201368.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"771_CR44","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1007\/s12325-020-01292-3","volume":"37","author":"D Ding","year":"2020","unstructured":"Ding D, Hu H, Liao M, Shi Y, She L, Yao L, et al. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Adv Ther. 2020;37(5):2116\u201326.","journal-title":"Adv Ther"},{"key":"771_CR45","doi-asserted-by":"publisher","first-page":"669195","DOI":"10.3389\/fonc.2021.669195","volume":"11","author":"G Liu","year":"2021","unstructured":"Liu G, Kang S, Wang X, Shang F. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. Front Oncol. 2021;11:669195.","journal-title":"Front Oncol"},{"issue":"11","key":"771_CR46","doi-asserted-by":"publisher","first-page":"e040691","DOI":"10.1136\/bmjopen-2020-040691","volume":"10","author":"Q Liu","year":"2020","unstructured":"Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, Tan C. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 2020;10(11):e040691.","journal-title":"BMJ Open"},{"key":"771_CR47","doi-asserted-by":"crossref","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T et al. \u00bfQu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? Gac Sanit. 2020 Mar-Apr;34(2):189\u201393.","DOI":"10.1016\/j.gaceta.2019.06.007"},{"issue":"2","key":"771_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.healthpol.2018.11.003","volume":"123","author":"L Maynou","year":"2019","unstructured":"Maynou L, Cairns J. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Health Policy. 2019;123(2):130\u20139.","journal-title":"Health Policy"},{"issue":"1","key":"771_CR49","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1017\/S0266462322000216","volume":"38","author":"Y Wang","year":"2022","unstructured":"Wang Y, Qiu T, Nikodem M, Francois C, Toumi M. A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment. Int J Technol Assess Health Care. 2022;38(1):e36.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"771_CR50","doi-asserted-by":"publisher","first-page":"e2219503","DOI":"10.1001\/jamanetworkopen.2022.19503","volume":"5","author":"EJ Tranv\u00e5g","year":"2022","unstructured":"Tranv\u00e5g EJ, Haaland \u00d8A, Robberstad B, Norheim OF. Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions. JAMA Netw Open. 2022;5(6):e2219503.","journal-title":"JAMA Netw Open"},{"key":"771_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CEOR.S66309","volume":"6","author":"I Chabot","year":"2014","unstructured":"Chabot I, Rocchi A. Oncology drug health technology assessment recommendations: Canadian versus UK experiences. Clin Outcomes Res. 2014;6:357\u201367.","journal-title":"Clin Outcomes Res"},{"key":"771_CR52","unstructured":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del Sistema Nacional de Salud. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica de medicamentos. 2023. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf."},{"key":"771_CR53","unstructured":"Ministerio de Sanidad. Nota de prensa: Sanidad publica la Gu\u00eda de Evaluaci\u00f3n Econ\u00f3mica de Medicamentos y Productos Sanitarios. 27 Feb 2024. Available from: https:\/\/www.sanidad.gob.es\/gabinete\/notasPrensa.do?id=6368."},{"key":"771_CR54","unstructured":"Regulation (EU). 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU."},{"key":"771_CR55","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.gaceta.2024.102417","volume":"38","author":"F Lobo","year":"2024","unstructured":"Lobo F, Oliva J, Vida J. Propuestas concretas para organizar una agencia de evaluaci\u00f3n de la eficiencia de tecnolog\u00edas y pol\u00edticas sanitarias (Specific proposals for organising an agency for evaluating the efficiency of health technologies and policies). Gac Sanit. 2024;38:102417.","journal-title":"Gac Sanit"},{"issue":"5","key":"771_CR56","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","volume":"21","author":"KN Vokinger","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21(5):664\u201370.","journal-title":"Lancet Oncol"},{"issue":"5","key":"771_CR57","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","volume":"28","author":"A Vivot","year":"2017","unstructured":"Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015. Ann Oncol. 2017;28(5):1111\u20136.","journal-title":"Ann Oncol"},{"key":"771_CR58","doi-asserted-by":"crossref","unstructured":"Pinilla-Dominguez P, Pinilla-Dominguez J. Challenges and reforms in Spain\u2019s health technology assessment system: analysis of criteria influencing medicines\u2019 reimbursement decisions between 2019 and 2022 in Spain. Eur J Health Econ. 2025 May 9.","DOI":"10.1007\/s10198-025-01790-7"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00771-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:35:19Z","timestamp":1784079319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00771-8","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"90"}}